​

KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KALV Stock Forecast

KalVista Pharmaceuticals (KALV) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $32.33, with a high of $37.00 and a low of $28.00. This represents a 115.68% increase from the last price of $14.99.

$5 $12 $19 $26 $33 $40 High: $37 Avg: $32.33 Low: $28 Last Closed Price: $14.99

KALV Stock Rating

KalVista Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

KALV Price Target Upside V Benchmarks

TypeNameUpside
StockKalVista Pharmaceuticals115.68%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$34.50$32.33
Last Closing Price$14.99$14.99$14.99
Upside/Downside-130.15%115.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2627---9
Jan, 2627---9
Dec, 2527---9
Nov, 2537---10
Oct, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 09, 2026Andrew FeinH.C. Wainwright$37.00$15.82133.88%146.83%
Jan 06, 2026Needham$32.00$15.66104.34%113.48%
Nov 11, 2025JMP Securities$28.00$10.89157.12%86.79%
Nov 05, 2024Serge BelangerNeedham$28.00$11.25148.89%86.79%
Sep 06, 2024Andrew FeinH.C. Wainwright$20.00$12.8755.40%33.42%
Sep 06, 2024Joseph SchwartzLeerink Partners$20.00$12.8755.40%33.42%
Jul 08, 2022Needham$38.00$10.98246.08%153.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2026Cowen & Co.BuyBuyhold
Jan 09, 2026H.C. WainwrightBuyBuyhold
Jan 09, 2026CitigroupOutperformOutperformhold
Jan 06, 2026NeedhamBuyBuyhold
Dec 03, 2025Cowen & Co.BuyBuyhold
Nov 11, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 12, 2025CitigroupOutperformOutperformhold
Sep 06, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024Leerink PartnersOutperformOutperformhold
Feb 03, 2023SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 $5 Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported$-3.44-----
Avg Forecast$-3.03$-3.63$-2.76$-1.06$0.68$2.39
High Forecast$-2.85$-3.46$-1.74$-0.02$1.14$4.03
Low Forecast$-3.23$-3.83$-3.56$-2.20$0.38$1.33
Surprise %13.53%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported------
Avg Forecast$4.46M$5.92M$42.74M$149.88M$271.40M$384.00M
High Forecast$6.81M$9.04M$58.41M$149.88M$414.34M$586.24M
Low Forecast$2.94M$3.91M$35.87M$149.88M$179.15M$253.47M
Surprise %------

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported$-126.64M$-183.44M----
Avg Forecast$-111.87M$-134.12M$-97.52M$-58.31M$24.92M$87.92M
High Forecast$-104.85M$-127.38M$-63.97M$-735.73K$41.99M$148.12M
Low Forecast$-118.88M$-140.86M$-131.08M$-80.93M$13.91M$49.07M
Surprise %13.21%36.77%----

KALV Forecast FAQ

Is KalVista Pharmaceuticals stock a buy?

KalVista Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that KalVista Pharmaceuticals is a favorable investment for most analysts.

What is KalVista Pharmaceuticals's price target?

KalVista Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $32.33 over the next 12 months. The price target range spans from $28 at the low end to $37 at the high end, suggesting a potential 115.68% change from the previous closing price of $14.99.

How does KalVista Pharmaceuticals stock forecast compare to its benchmarks?

KalVista Pharmaceuticals's stock forecast shows a 115.68% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for KalVista Pharmaceuticals over the past three months?

  • February 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is KalVista Pharmaceuticals’s EPS forecast?

KalVista Pharmaceuticals's average annual EPS forecast for its fiscal year ending in April 2026 is $-2.76, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-1.06 in 2027, $0.68 in 2028, and $2.39 in 2029.

What is KalVista Pharmaceuticals’s revenue forecast?

KalVista Pharmaceuticals's average annual revenue forecast for its fiscal year ending in April 2026 is $42.74M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $149.88M, followed by $271.4M for 2028, and $384M for 2029.

What is KalVista Pharmaceuticals’s net income forecast?

KalVista Pharmaceuticals's net income forecast for the fiscal year ending in April 2026 stands at $-97.522M, representing a -46.84% decrease from the reported $-183M in 2025. Projections indicate $-58.309M in 2027, $24.92M in 2028, and $87.92M in 2029.